Peptomyc

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has widely been considered as an undruggable cancer target. Published today in the journal Nature Medicine, results of the first-in-human phase I trial of OMO-103 demonstrate...
C/ Natzaret, 115-117 Barcelona, Spain, 08035

+34 932 543 450 (ext. 8636)